Results 11 to 20 of about 29,136 (254)

Heterologous Prime-boost COVID-19 Vaccination

JK Science, 2021
There is a significant recent international interest in heterologous prime-boost COVID-19 vaccination. It may prove useful in avoiding the supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out in any country including ...
Vishal R. Tandon, Annil Mahajan
doaj   +1 more source

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination [PDF]

Nature, 2021
Abstract Following severe adverse reactions in patients vaccinated with the AstraZeneca ChadOx1 (Chad) vaccine, European health authorities have recommended that patients under the age of 55 who received one dose of Chad vaccine receive a second dose of Pfizer BNT162b2 (BNT) vaccine as a booster.
Bruno Pozzetto, Vincent Legros, Sophia Djebali, Véronique Barateau, Nicolas Guibert, Marine Villard, Loïc Peyrot, Omran Allatif, Jean-Baptiste Fassier, Amélie Massardier-Pilonchéry, Karen Brengel-Pesce, Melyssa Yaugel-Novoa, Solène Denolly, Bertrand Boson, Thomas Bourlet, Antonin Bal, Martine Valette, Thibault Andrieu, Bruno Lina, Kahina Saker, Christelle Compagnon, Bouchra Mokdad, Constance d’Aubarede, Virginie Pitiot, Vanessa Escuret, Florence Morfin, Mary-Anne Trabaud, Margaux Prieux, Valérie Dubois, Laurence Josset, Soizic Daniel, François-Loïc Cosset, Stéphane Paul, Thierry Defrance, Jacqueline Marvel, Thierry Walzer, Sophie Trouillet-Assant   +36 more
openaire   +5 more sources

BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists

Frontiers in Immunology, 2023
BackgroundVaccines can have beneficial off-target (heterologous) effects that alter immune responses to, and protect against, unrelated infections. The heterologous effects of COVID-19 vaccines have not been investigated in children.AimTo investigate ...
Andrés Noé, Andrés Noé, Thanh D. Dang, Christine Axelrad, Emma Burrell, Susie Germano, Sonja Elia, David Burgner, David Burgner, David Burgner, Kirsten P. Perrett, Kirsten P. Perrett, Kirsten P. Perrett, Nigel Curtis, Nigel Curtis, Nigel Curtis, Nicole L. Messina, Nicole L. Messina   +17 more
doaj   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Heterologous vaccine regimens against COVID-19 [PDF]

The Lancet, 2021
The rapid development of vaccines against COVID-19 is the biggest achievement of science in the fight against the pandemic. Although the efficacy and safety of all approved vaccines have been demonstrated in large clinical trials, recent safety signals have been reported, highlighting the importance of post-marketing surveillance with study populations
Duarte-Salles, Talita, Prieto-Alhambra, Daniel, Prieto Alhambra, D. (Dani)   +2 more
openaire   +2 more sources

Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

iScience, 2023
Summary: The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters ...
Daryl Geers, Roos S.G. Sablerolles, Debbie van Baarle, Neeltje A. Kootstra, Wim J.R. Rietdijk, Katharina S. Schmitz, Lennert Gommers, Susanne Bogers, Nella J. Nieuwkoop, Laura L.A. van Dijk, Eva van Haren, Melvin Lafeber, Virgil A.S.H. Dalm, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Anke L.W. Huckriede, Alessandro Sette, Alba Grifoni, Rik L. de Swart, Marion P.G. Koopmans, P. Hugo M. van der Kuy, Corine H. GeurtsvanKessel, Rory D. de Vries   +23 more
doaj   +1 more source

Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms

Vaccines, 2022
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination.
Anna Parys, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter, Kristien Van Reeth   +6 more
doaj   +1 more source

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

The Lancet Regional Health. Europe, 2021
Summary: Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
Peter Nordström, Marcel Ballin, Anna Nordström   +2 more
doaj   +1 more source

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Vaccines, 2022
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens.
Ulrika Marking, Sebastian Havervall, Nina Greilert-Norin, Henry Ng, Kim Blom, Peter Nilsson, Mia Phillipson, Sophia Hober, Charlotta Nilsson, Sara Mangsbo, Wanda Christ, Jonas Klingström, Max Gordon, Mikael Åberg, Charlotte Thålin   +14 more
doaj   +1 more source

Heterologous effects of vaccination and trained immunity [PDF]

Clinical Microbiology and Infection, 2019
Vaccines are applied to large populations, but only recently has research into immunologic responses and mechanisms started to increase exponentially. Some live vaccines, such as the tuberculosis vaccine bacillus Calmette-Guérin, protect against other infections nonspecifically by eliciting complex immune responses which are not specific antibody ...
Gyssens, I.C.J., Netea, M.G., Netea, M.G.   +2 more
openaire   +3 more sources